495 related articles for article (PubMed ID: 35323317)
1. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Ghelani GH; Zerdan MB; Jacob J; Spiess PE; Li R; Necchi A; Grivas P; Kamat A; Danziger N; Lin D; Huang R; Decker B; Sokol ES; Cheng L; Pavlick D; Ross JS; Bratslavsky G; Basnet A
Urol Oncol; 2023 Dec; 41(12):486.e15-486.e23. PubMed ID: 37821306
[TBL] [Abstract][Full Text] [Related]
4. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
5. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
6. Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma.
Chen X; Ou Z; Wang L; Zhang Z; Fan X; Liu H; Wang W; Zhang Y; Zhu J; Liang X; Lou F; Cao S; Yao Y; Wang H; Yao X
Mol Carcinog; 2022 Mar; 61(3):311-321. PubMed ID: 34729830
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
Nishiyama H; Tsuzuki T; Ohyama C; Matsuyama H; Shinozaki K; Hayashi Y; Hayashi N; Koto R; Shin E; Ogawa O
Int J Clin Oncol; 2023 Oct; 28(10):1398-1410. PubMed ID: 37498492
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
Wang Y; Chen L; Ju L; Xiao Y; Wang X
Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
[TBL] [Abstract][Full Text] [Related]
10. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
13. High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.
Voutsadakis IA
Target Oncol; 2020 Feb; 15(1):127-138. PubMed ID: 31741177
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
15. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors.
Chawla NS; Sayegh N; Tripathi N; Govindarajan A; Zengin ZB; Phillip EJ; Dizman N; Meza L; Muddasani R; Chehrazi-Raffle A; Malhotra J; Hsu J; Agarwal N; Pal SK; Tripathi A
Clin Genitourin Cancer; 2023 Feb; 21(1):69-75. PubMed ID: 36509613
[TBL] [Abstract][Full Text] [Related]
16. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma.
Zhang C; Shen L; Qi F; Wang J; Luo J
J Cell Physiol; 2020 Apr; 235(4):3849-3863. PubMed ID: 31596511
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
18. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
19. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
20. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]